New therapeutic strategies are needed for patients with atherosclerosis. Despite failing to reach its primary end point, a multicenter, phase II, randomized, placebo-controlled trial of RVX-208—an oral, synthetic quinazoline molecule that stimulates expression of endogenous apolipoprotein A-I—has provided somewhat encouraging results. Nevertheless, detailed investigations are still needed if we are ever to realize the full atheroprotective potential of novel HDL-targeted therapies.
This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
Impact of low high-density lipoprotein-cholesterol level on 2-year clinical outcomes after acute myocardial infarction in patients with diabetes mellitus
Lipids in Health and Disease Open Access 18 November 2016
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Nicholls, S. J. et al. Efficacy and safety of a novel oral inducer of apolipoprotein A-I synthesis in statin-treated patients with stable coronary artery disease: a randomized controlled trial. J. Am. Coll. Cardiol. doi:10.1016/j.jacc.2010.11.015.
Shah, P. K., Kaul, S., Nilsson, J. & Cercek, B. Exploiting the vascular protective effects of high-density lipoprotein and its apolipoproteins: an idea whose time for testing is coming, part I. Circulation 104, 2376–2383 (2001).
Shah, P. K., Kaul, S., Nilsson, J. & Cercek, B. Exploiting the vascular protective effects of high-density lipoprotein and its apolipoproteins: an idea whose time for testing is coming, part II. Circulation 104, 2498–2502 (2001).
Shah, P. K. Evolving concepts on benefits and risks associated with therapeutic strategies to raise HDL. Curr. Opin. Cardiol. 25, 603–608 (2010).
Heinecke, J. W. The protein cargo of HDL: implications for vascular wall biology and therapeutics. J. Clin. Lipidol. 4, 371–375 (2010).
Barter, P. J. et al. Effects of torcetrapib in patients at high risk for coronary events. N. Engl. J. Med. 357, 2109–2122 (2007).
Shah, P. K. The yin and yang of cholesteryl ester transfer protein in cardiovascular disease. Circulation 120, 2408–2410 (2009).
Bailey, D. et al. RVX-208: a small molecule that increases apolipoprotein A-I and high-density lipoprotein cholesterol in vitro and in vivo. J. Am. Coll. Cardiol. 55, 2580–2589 (2010).
van der Steeg, W. A. et al. High-density lipoprotein cholesterol, high-density lipoprotein particle size, and apolipoprotein A-I: significance for cardiovascular risk: the IDEAL and EPIC-Norfolk studies. J. Am. Coll. Cardiol. 51, 634–642 (2008).
Khera, A. V. et al. Cholesterol efflux capacity, high-density lipoprotein function, and atherosclerosis. N. Engl. J. Med. 364, 127–135 (2011).
Author information
Authors and Affiliations
Ethics declarations
Competing interests
The author declares that he is a past advisor for Resverlogix.
Rights and permissions
About this article
Cite this article
Shah, P. Targeting endogenous apo A-I—a new approach for raising HDL. Nat Rev Cardiol 8, 187–188 (2011). https://doi.org/10.1038/nrcardio.2011.37
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrcardio.2011.37
This article is cited by
-
HDL, ApoA-I and ApoE-Mimetic Peptides: Potential Broad Spectrum Agent for Clinical Use?
International Journal of Peptide Research and Therapeutics (2022)
-
Impact of low high-density lipoprotein-cholesterol level on 2-year clinical outcomes after acute myocardial infarction in patients with diabetes mellitus
Lipids in Health and Disease (2016)
